Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115108 - EGFR INHIBITORS AND THEIR USE IN THE TREATMENT OF NEUROATHIC PAIN

Publication Number WO/2020/115108
Publication Date 11.06.2020
International Application No. PCT/EP2019/083620
International Filing Date 04.12.2019
IPC
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 31/4709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines and containing further heterocyclic rings
A61K 31/497
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4965Non-condensed pyrazines
497containing further heterocyclic rings
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Applicants
  • SØRLANDET SYKEHUS HF [NO]/[NO]
Inventors
  • CAMERON, Marte Gronlie
  • MJALAND, Svein
  • KERSTEN, Christian
Agents
  • MERCK SERONO S.A. INTELLECTUAL PROPERTY
Priority Data
18210736.706.12.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) EGFR INHIBITORS AND THEIR USE IN THE TREATMENT OF NEUROATHIC PAIN
(FR) INHIBITEURS D'EGFR ET LEUR UTILISATION DANS LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
Abstract
(EN)
The present invention concerns biomarkers which aid in the stratification of patients afflicted with neuropathic pain and in vitro methods to determine the abundance of said biomarkers to predict the likelihood of response to a neuropathic pain treatment with an EGFR inhibitor of a patient inflited with neuropathic pain. The invention further pertains to EGFR inhibitors for use in the treatment of neuropathic pain in patients which based on their biomarker status are likely to respond to such treatment. The invention further provides a method of treatment of patients afflicted with neuropathic pain which are likely to respond to a treatment with an EGFR inhibitor.
(FR)
La présente invention concerne des biomarqueurs qui aident à la stratification de patients atteints de douleur neuropathique et des procédés in vitro pour déterminer l'abondance desdits biomarqueurs pour prédire la probabilité de réponse à un traitement de la douleur neuropathique par un inhibiteur d'EGFR d'un patient souffrant de douleur neuropathique. L'invention concerne en outre des inhibiteurs d'EGFR destinés à être utilisés dans le traitement de la douleur neuropathique chez des patients qui, sur la base de leur statut de biomarqueurs, sont susceptibles de répondre à un tel traitement. L'invention concerne en outre une méthode de traitement de patients atteints de douleur neuropathique qui sont susceptibles de répondre à un traitement par un inhibiteur d'EGFR.
Latest bibliographic data on file with the International Bureau